Clinical trial / 2009
Adding Aloe arborescens to chemotherapy improved tumor regression and 3-year survival in metastatic cancer.
In a randomized trial of 240 patients with metastatic solid tumors, participants received chemotherapy alone or chemotherapy with oral Aloe arborescens (10 ml three times daily). Patients receiving adjuvant Aloe had significantly higher percentages of objective tumor regression and disease control compared to chemotherapy alone. The percentage of patients surviving at 3 years was also significantly higher in the Aloe group.
- Study type
- Randomized controlled trial
- Who was studied
- 240 patients with metastatic solid tumors
- What was measured
- Tumor regression rate, disease control, 3-year survival
THE PAPER
A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer.
Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, Mora A, Porro G. In Vivo, 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.